Agilent Technologies, Inc. (NYSE:A) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Agilent Technologies is a broad-based OEM of test and measurement equipment. The company’s fiscal third quarter results were above the Zacks Consensus estimate. Year to date, the stock has slightly underperformed the Industry it belongs to. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base and diversification of geographic and industrial operations for growth. Also, the company’s focus on aligning investments so as to be oriented toward more attractive growth avenues and innovative high-margin product launches are positives. Agilent’s broad-based portfolio and increased focus on segments offer higher growth potential. However, the macro weakness in the U.S. and Europe and forex headwinds remain concerns.”
Other equities research analysts have also recently issued research reports about the company. Deutsche Bank AG set a $68.00 target price on Agilent Technologies and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Morgan Stanley reaffirmed an “overweight” rating on shares of Agilent Technologies in a research note on Tuesday. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $70.00 target price on shares of Agilent Technologies in a research note on Wednesday, August 16th. Bank of America Corporation raised their price objective on Agilent Technologies from $66.00 to $68.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 16th. Finally, Janney Montgomery Scott raised their price objective on Agilent Technologies from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, August 16th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $66.70.
Agilent Technologies (NYSE:A) opened at $67.31 on Thursday. Agilent Technologies has a 1 year low of $42.92 and a 1 year high of $68.67. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.76 and a current ratio of 3.22. The stock has a market capitalization of $21,710.52, a PE ratio of 29.46, a PEG ratio of 2.64 and a beta of 1.27.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the company earned $0.49 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. research analysts predict that Agilent Technologies will post 2.32 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Agilent Technologies, Inc. (A) Stock Rating Lowered by Zacks Investment Research” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/11/16/agilent-technologies-inc-a-stock-rating-lowered-by-zacks-investment-research-2.html.
In other Agilent Technologies news, Director Boon Hwee Koh sold 4,500 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total value of $286,335.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Didier Hirsch sold 1,200 shares of the business’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total value of $79,200.00. Following the completion of the sale, the chief financial officer now owns 164,202 shares in the company, valued at $10,837,332. The disclosure for this sale can be found here. Insiders have sold 152,713 shares of company stock worth $9,682,305 over the last quarter.
Several institutional investors and hedge funds have recently modified their holdings of the business. Dupont Capital Management Corp bought a new stake in shares of Agilent Technologies during the 3rd quarter valued at $101,000. Balentine LLC raised its stake in shares of Agilent Technologies by 2.9% during the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 50 shares during the period. Sun Life Financial INC raised its stake in shares of Agilent Technologies by 26,144.4% during the 2nd quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after purchasing an additional 2,353 shares during the period. Acrospire Investment Management LLC raised its stake in shares of Agilent Technologies by 92.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after purchasing an additional 1,200 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of Agilent Technologies by 5.3% during the 2nd quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 131 shares during the period.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.